About Inward rectifier potassium channel 2
Inward rectifier potassium channel 2 (KCNJ2) is a protein
from Homo sapiens identified by UniProt accession
P63252, 427 residues long.
MolForge cross-references it against 0 known binders and
318 disease associations.
Target properties
| Protein name | Inward rectifier potassium channel 2 |
| UniProt accession | P63252 |
| Gene | KCNJ2 |
| Organism | Homo sapiens |
| Length | 427 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (318)
Diseases linked to this target (Open Targets).
- Andersen-Tawil syndrome · score 0.85
- Cardiodysrhythmic potassium-sensitive periodic paralysis · score 0.82
- short QT syndrome type 3 · score 0.73
- atrial fibrillation, familial, 9 · score 0.67
- atrial fibrillation · score 0.67
- Familial short QT syndrome · score 0.64
- Abnormality of the cardiovascular system · score 0.52
- periodic paralysis · score 0.51
- lean body mass · score 0.46
- appendicular lean mass · score 0.45
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P63252-F1 | alphafold | PREDICTED | 81.63 | — |
Amino-acid sequence (427 residues)
MGSVRTNRYS IVSSEEDGMK LATMAVANGF GNGKSKVHTR QQCRSRFVKK DGHCNVQFIN VGEKGQRYLA DIFTTCVDIR WRWMLVIFCL AFVLSWLFFG CVFWLIALLH GDLDASKEGK ACVSEVNSFT AAFLFSIETQ TTIGYGFRCV TDECPIAVFM VVFQSIVGCI IDAFIIGAVM AKMAKPKKRN ETLVFSHNAV IAMRDGKLCL MWRVGNLRKS HLVEAHVRAQ LLKSRITSEG EYIPLDQIDI NVGFDSGIDR IFLVSPITIV HEIDEDSPLY DLSKQDIDNA DFEIVVILEG MVEATAMTTQ CRSSYLANEI LWGHRYEPVL FEEKHYYKVD YSRFHKTYEV PNTPLCSARD LAEKKYILSN ANSFCYENEV ALTSKEEDDS ENGVPESTST DTPPDIDLHN QASVPLEPRP LRRESEI
Explore Inward rectifier potassium channel 2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets